Stock Evaluator: Scilex Holding Company (SCLX)

Scilex Holding Company SCLX

$0.57 -0.08 -12.95%
November 20, 2026 3:59:58 PM EST November 10, 2021 Volume: 198,279
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.

Commentary & Analysis


Financial Summary

Share Statistics SCLX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $4.0 $421.5 5%
Shares Out (Mil) 6.9 46.9 17%
Institutional Ownership 71.5% 82.0% 43%
Float (Mil) 5.7 49.2 13%
Beta 1.74 0.68 87%
Avg Daily Volume (000s) 141 347 40%
Price Change
(52-week)
(96.7%) 49.3% 3%
Growth SCLX Industry
Median
Percentile
(All Stocks)
Sales (5yr) 5.1% 6.4% 37%
Net Income (5yr) (49.8%) (1.3%) 7%
EPS (5yr) (23.7%) 15.1% 11
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 15.0% (15.0%) 72%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials SCLX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $32 $275 16%
Net Income (TTM) (Mil) ($447) ($11) 3%
EPS (TTM) ($51.596) ($0.700) 1%
Operating Cash Flow (TTM) (Mil) ($17) ($7) 16%
Net Cash Flow (TTM) (Mil) ($4) $1 38%
Long-Term Debt (Q1) (Mil) $18 $6 32%
Enterprise Value (Q1) (Mil) $144 $331 25%
Valuation SCLX Industry
Median
Percentile
(All Stocks)
P/B na 2.08 na
P/E na 20.9 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.1 na
Ratios SCLX Industry
Median
Percentile
(All Stocks)
Gross Margin 55.5% 69.5% 68%
Net Margin na 3.6% na
ROA (265.1%) (23.8%) 1%
ROE 160.5% (24.2%) 98%
Liabilities to Assets 222.5% 31.6% 99%
F-Score 2 3 7%

Scilex Holding Company did not pass any screens on 11/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors